A detailed history of Bank Of America Corp transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Bank Of America Corp holds 1,697,152 shares of HALO stock, worth $91.7 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
1,697,152
Previous 1,187,659 42.9%
Holding current value
$91.7 Million
Previous $43.9 Million 57.28%
% of portfolio
0.01%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$33.68 - $41.95 $17.2 Million - $21.4 Million
509,493 Added 42.9%
1,697,152 $69 Million
Q4 2023

Feb 14, 2024

BUY
$33.32 - $42.1 $2.22 Million - $2.8 Million
66,511 Added 5.93%
1,187,659 $43.9 Million
Q2 2023

Aug 14, 2023

SELL
$30.28 - $38.74 $11.4 Million - $14.5 Million
-375,408 Reduced 25.08%
1,121,148 $40.4 Million
Q1 2023

May 12, 2023

BUY
$32.86 - $55.7 $13.9 Million - $23.6 Million
422,949 Added 39.4%
1,496,556 $57.2 Million
Q4 2022

Feb 10, 2023

SELL
$40.06 - $59.44 $2.24 Million - $3.32 Million
-55,937 Reduced 4.95%
1,073,607 $61.1 Million
Q3 2022

Nov 14, 2022

BUY
$38.53 - $51.78 $14.4 Million - $19.4 Million
375,019 Added 49.7%
1,129,544 $44.7 Million
Q2 2022

Aug 12, 2022

BUY
$37.35 - $48.3 $981,296 - $1.27 Million
26,273 Added 3.61%
754,525 $33.2 Million
Q1 2022

May 16, 2022

BUY
$31.97 - $41.06 $2.38 Million - $3.05 Million
74,395 Added 11.38%
728,252 $29 Million
Q4 2021

Feb 08, 2022

SELL
$31.82 - $40.75 $2.51 Million - $3.21 Million
-78,841 Reduced 10.76%
653,857 $26.3 Million
Q3 2021

Nov 15, 2021

BUY
$38.47 - $46.42 $2.19 Million - $2.65 Million
57,050 Added 8.44%
732,698 $29.8 Million
Q2 2021

Sep 13, 2021

BUY
$38.84 - $51.31 $26.2 Million - $34.7 Million
675,648 New
675,648 $30.7 Million

Others Institutions Holding HALO

About HALOZYME THERAPEUTICS, INC.


  • Ticker HALO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 139,288,992
  • Market Cap $7.53B
  • Description
  • Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...
More about HALO
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.